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ABSTRACT
More persons died from drug overdoses in the United States since 2000 than during any
past years on record. There were approximately one and a half times more drug
overdose deaths in the United States than deaths from motor vehicle crashes in 2015.
Opioids, primarily prescription pain relievers and heroin, are the main drugs associated
with overdose deaths. The 2014 data demonstrates that the United States opioid
overdose epidemic includes two distinct but interrelated trends: a 15-year increase in
overdose deaths involving prescription opioid pain relievers along with a recent rise in
illicit opioid overdose deaths, driven by heroin. Natural and semisynthetic opioids,
oxycodone and hydrocodone which are the commonly prescribing drugs, continue to be
involved in more overdose deaths than any other opioid type. Prescription painkillers
overdose death rates had declined in 2012 compared with 2011, and had held steady in
2013, but then a sudden increase of 9% was observed in 2014. Five states with the
highest rates of drug overdose deaths in 2014 were West Virginia (35.5 deaths per
100,000), New Mexico (27.3), New Hampshire (26.2), Kentucky (24.7) and Ohio (24.6).
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Due to implementation of federal and state guidelines, laws and regulations along with
education and various medical strategies, the drug overdose deaths in NM has declined
by 7.5% and in 2015, the state has ranked as the eighth highest in the drug overdose
deaths in US.
The long-term goal of this line of research is to decrease deaths and emergency
department (ED) visits related to opioid overdose in the state of New Mexico. The
overall objective of this specific initial project is to create a survey, by identifying the
most frequent and impactful barriers faced by the buprenorphine prescribers and nonprescribers for treating the opioid addicted population in NM. The research study has
one specific aim that is descriptive and exploratory in nature: To create a new survey
that will later be used to assess the frequency of barriers associated with prescribing
buprenorphine in New Mexico (NM) for treating opioid addicted patients. This
contribution is also important because our new survey is potentially generalizable to any
state in the United States to identify these barriers.
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Chapter 1
Introduction
The United States is undergoing an epidemic of drug overdose related
deaths. Nearly half a million have died between 2000 and 2015 and every day
91 Americans die from an opioid overdose (1,28). Since 2000, the rate of deaths
from drug overdoses has increased 137% with a 200% increase involving opioids
– chiefly prescription painkillers and heroin (1). New Mexico has led the nation in
drug overdose deaths for the last two decades and the death rate has tripled
since 1990 to become the leading cause of unintentional injury in the state (2). In
2015, the drug overdose death rate in the United States was 13.5 per 100,000,
whereas in New Mexico, it was 24.4 per 100,000 (2). Opioids, chiefly
prescription painkillers and heroin, are the leading cause of overdose deaths.
According to the New Mexico Department of Health, 449 and 536 residents died
due to drug overdose in 2013 and 2014 respectively (2). While deaths due to
illicit drugs have remained steady during the past decade, deaths due to opioids,
particularly prescription drugs, have increased dramatically nationally. According
to American Society of Addiction Medicine opioid addiction 2016 facts and figure
data, “Drug overdose is the leading cause of accidental death in the US, with
55,403 lethal drug overdoses in 2015. Opioid addiction is driving this epidemic,
with 20,101 overdose deaths related to prescription pain relievers, and 12,990
overdose deaths related to heroin in 2015” (8).
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As stated in New Mexico Substance Abuse Epidemiology Profile August
2014, 49% of drugs causing unintentional overdose death were prescription
opioids (3). The rate of ED visits due to opioid overdose has also increased
approximately 30% between 2010 and 2013 in the state (4). In 2013, there were
2,506 ED visits due to drug overdose at the rate of 122.8 visits per 100,000
populations, the rate of prescription opioid overdose related ED visits was 60.4
visits per 100,000 populations and the rate of heroin overdose-related ED visits
was 26.9 visits per 100,000 populations (4). Drug abuse not only results in
overdose death and increased ED visits due to cardiovascular, pulmonary,
infectious disease (HIV, TB, Hepatitis B and C), psychiatric, and gastroenteritis
complaints but is also associated with other social determinants of adverse
health outcomes, including crime, violence, homelessness and loss of
productivity.
Since 1972, when the Food and Drug Administration (FDA) approved
methadone as a treatment for opioid abuse, millions of patients have been
successfully treated with it. However, the major concern is that methadone can
only be given in licensed substance abuse treatment facilities which have Opioid
Treatment Programs (OTPs), approved for Medication Assistant Treatment
(MAT). These programs are vigilantly oversight by states, Substance Abuse and
Mental Health Services Administration (SAMHSA), Department of Health and
Human Services (HHS) and Drug Enforcement Administration (DEA).
Unfortunately, only few OTPs exist in New Mexico, and patients often have to
drive for hours from one county to another to reach these treatment facilities.

2

Clinically, methadone is also associated with severe life threatening side effects
that include withdrawal, relapse, respiratory depression, cardiac rhythmic
abnormalities and death (5).
Due to tremendous increase in the use of prescription and nonprescription opioid in the US, a flexible and urgent treatment was critically
needed which has minimal side effects and can be easily prescribed from office
based practiced settings (OBS). In October 2002, finally FDA approved
buprenorphine which can be easily prescribed from OBS. Buprenorphine
represents the one of the latest advancements in in medication-assisted
treatment for opioid dependence. There have been two other medications
approved after buprenorphine, 1) extended release naltrexone known as vivitrol
which was approved for OUD after buprenorphine and buprenorphine implant
which is a long acting implant.
Like methadone, buprenorphine in combination with counseling and
behavioral therapies, provides a holistic treatment approach for people with
opioid dependency that has minimal side effects and is easily prescribed and
supervised from the office-based practice settings. When taken as prescribed,
buprenorphine is much more safe and effective compared to methadone with
considerably lower risk potential than other opioids. Its safety profile, ceiling
effect at high doses, formulated with naloxone to limit injection abuse, and lower
abuse potential compared to full opioid agonists make it a suitable and safer
medication for office-based treatment of opioid dependency (25).
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Despite the high efficacy of buprenorphine, New Mexico has only 255
Drug Addiction Treatment Act 2000 (DATA 2000) certified physicians who are
registered to prescribe buprenorphine in the state according to the Substance
Abuse and Mental Health Service Administration website, (6). But, according to
the New Mexico Pharmacy Board, out of 255, only 111 are actively prescribing
buprenorphine and have a minimum of 20 patients in last fourth quarter of 2016
(These data are obtained from New Mexico Department of Health on March 31,
2017).
Many counties in NM have a high rate of heroin use, but have no or only 1
or 2 physicians prescribing buprenorphine. According to the New Mexico
Substance Abuse Epidemiology Profile August 2014, in 2013 the life time rate of
heroin use in Valencia was 8.6%, 7.8% in San Miguel and 6.8 % in Lincoln
counties of New Mexico (3). Based on the SAMHSA database, Lincoln County
has 0 buprenorphine physician prescribers, Valencia County has one, and San
Miguel County has 8 (6). Similarly, according to the National Directory of Drug
and Alcohol Abuse treatment program, Lincoln and San Miguel County have only
one treatment facility available each, and Valencia County has none (7). The
table below shows the number of buprenorphine prescribers in relation to
counties, population and facilities.
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Table 1: Buprenorphine Prescribing Physicians by High Opioid Addiction NM
Counties
Counties

Lifetime
Heroin
Use, 2013

Cities in
County

Population
(Census
2010)

Buprenorphine
Prescribers
(SAMHSA)

Drug and Alcohol
Abuse Facilities
(National Directory of
Drug and Alcohol
Abuse Treatment
Program)

Valencia
County

8.6%

Belen,
Rio Communities

76,569

1 prescriber in
Belen, 0
prescriber in Rio

None

Lincoln
County

6.8%

20,497

No prescriber in
any city

1 treatment facility in
Ruidoso

San
Miguel

7.8%

Capitan,
Carrizozo,
Corona, Glencoe,
Honda, Nogal,
Ruidoso, Downs,
San Patricio,
Tinnie
Las Vegas,
Pecos, Conchas
Dam, New
Mexico, More

29,393

6 prescribers in
Las Vegas.
2 prescriber in
Pecos

1 treatment facility in Las
Vegas

Potential Harmful effects of Substance Abuse in United States
Health care costs are rising and drug abuse poses a large burden on an
already strained system. Illicit drugs are estimated to cost American society
approximately $193 billion each year (24). The greatest cost of drug abuse is
either lost directly to overdose, or through drug abuse-related diseases such as
tuberculosis, sexually transmitted diseases (STDs), hepatitis, and acquired
immunodeficiency syndrome (AIDS) (20). Other costs of drug abuse are due to
traffic accidents caused by alcohol- and drug-impaired drivers; street crime
committed by addicts to support their addiction; loss of work productivity and
resources expended to apprehend, sentence, treat, and incarcerate drug abusers
(20).
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A strong correlation also exists between drug abuse and homelessness.
Drug users are less dependable employees than other workers and have
decreased workplace productivity. They are more likely to have taken an
unexcused absence compared to drug-free workers. Drug users get fired more
frequently and also switch or left jobs more frequently compared to non-drug user
employees. This high turnover increases training and other productivity-related
costs to American businesses (20).
Despite of the fact that an efficacious drug buprenorphine is available in
the market, still many of opioid use disorder patients are unable to access
physicians who are actively prescribing buprenorphine. The purpose of this
study is to find out specifically why buprenorphine is not effectively prescribed in
New Mexico. I have reviewed 39 studies related to buprenorphine and was
astonished to see that only one study has been conducted in New Mexico and
rest of them were either conducted in others states or nations, out of which some
are qualitative and some are quantitative studies. Peer reviewed and published
studies mentioned several barriers to physicians becoming prescribers of
buprenorphine for opioid dependent patients: (1) buprenorphine training, (2) DEA
auditing, (3) clinical office base setting stigma, (4) lack of provider interest,
knowledge and expertise in treating opioid use disorder patients, (5) inadequate
financial support from health insurance, Medicaid or Medicare, (6) lack of
institutional training and support, (7) complex patient populations (8) shortage of
physicians in rural areas are the barriers identified by physicians in some of the
published research studies and, (9) hesitation in adopting buprenorphine
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treatment by PCPs in office based settings. However, none of the articles has
been able to identify all the obstacles. Some share mutual barriers and some
identify other distinctive barriers.
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Studies of Buprenorphine Barriers faced by Physicians Nationally, Internationally
and in New Mexico
Studies Conducted Nationally
Over the past two decades, few studies have been conducted nationally to
identify the challenges faced by physicians in prescribing buprenorphine for
opioid use disorder patients.

Both qualitative and quantitative studies

recognized some of the multiple barriers faced by physicians in the United
States.
A telephone interview survey was conducted in 2010 in rural Washington
(9). Twenty-four out of thirty-three (73%) rural physicians mentioned four
important barriers which include: (1) inadequate financial support from Medicaid,
(2) lack of mental health and behavioral addiction treatment services, (3) difficulty
in finding consultants to assist in treating complex patients, and (4) shortage of
physicians in rural areas.
In 2010, a 34 item survey that asked about clinician’s beliefs and attitudes about
buprenorphine/naloxone diversion was completed by a national representative
sample of non-prescribing addiction treatment professionals at the Cape Cod
Symposium on Addictive Disorders in Hyannis, Massachusetts (10). The same
survey was also completed by a national representative sample of prescribers at
the American Academy of Addiction Psychiatry Symposium in Boca Raton, FL
also in 2010. Results from this study show that attitudes and beliefs were
associated with clinicians’ perceptions of danger from buprenorphine diversion.
Also, clinicians with greater number patient receiving buprenorphine believe that
barriers to access treatment was a major cause of buprenorphine diversion.
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Another study was conducted in 2005 in Massachusetts, which
investigated the barriers that were affecting the accessibility of opioid
detoxification with buprenorphine in the state (11). Three hundred and fifty-six
buprenorphine waiver physicians were selected and a survey was sent through
the mail, out of which 235 physicians responded (66%) to the survey. Two -thirds
of non-prescribers and half of the prescribers reported at least one barrier. The
more common barriers among DEA waiver prescribers were reimbursement and
pharmacy issues. The more common barriers for those with a DEA waiver but
not prescribing were insufficient staff knowledge and low demand of
buprenorphine. Insufficient office, nursing and institutional support were barriers
reported in both groups.
A recent study published in February 2015 included 173 out of 188 (92%)
of accredited psychiatry residency programs in the United States (12). Forty-one
programs responded with a response rate of 24%. Sixty-eight percent of
programs provide residents an experience of using buprenorphine for
detoxification, whereas 78% provide experience to use buprenorphine for
maintenance treatment. Only 15% required that residents complete the
buprenorphine training as a part of residency. Sixty-one percent offered optional
training and 24% did not offer any training. Major barriers in promoting
buprenorphine treatment for opioid use disorder patients
include the lack of institutional support to provide access to the buprenorphine
training or understanding the need to produce more buprenorphine prescribers in
the epidemic of opioid overdose death are
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A study published in 2015 was conducted in rural settings of New
Hampshire and Vermont and included both qualitative and quantitative questions
to understand the barriers to adoption of BMT among family physicians in a
primarily rural area in the Unites States (13). One hundred and eight family
practitioners completed it. Only 10% were the prescribers. Eighty-eight percent
reported inadequately trained staff, 80% reported insufficient time, 49% reported
inadequate office based settings, and 37% reported cumbersome regulation as a
barrier.
A systemic review was published in Substance Abuse Journal in 2015 in
which the Medline database was searched for all the studies conducted on
examining the office based provider’s acceptance or satisfaction with office
based treatment of opioid addicted patients. Eight studies met the inclusion
criteria, out of which four studies concluded that providers had a positive
perception related to the efficacy of opioid agonist treatment, the other four
studies indicated that providers believed that opioid use disorder patients were
more complex compared to other patients in their practices. Three out of these
eight studies also mentioned that additional support, including psychologists,
counselors, social workers, etc., is needed to take care of opioid use disorder
patients in office based treatment practices (17).
A study was conducted in Ohio in 2014 in which 41 Ohio specialty
addiction treatment organizations were asked to complete a survey of their
buprenorphine practices and availability of buprenorphine prescribers. Data was
collected on pharmacotherapies used in the treatment of opioid dependence,
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buprenorphine prescribing capacity, arrangements of the treatment organizations
with prescribing physicians and also about the barriers encountered in hiring new
physician to prescribe buprenorphine. Out of 41, 37 treatment organizations
responded (90%). Twenty-nine treatment facilities (78%) actually prescribed
buprenorphine. Fourteen (48%) of these 29 treatment facilities reported
insufficient prescribing capacity. Out of these 14, 7 (50%) mentioned that they
had to turn patients away from buprenorphine therapy due to limited physician
prescribing capacity (18).
A semi structured telephone interviews of key personnel at a national
sample of Veterans Health Administration (VHA) facilities with patient populations
having high prevalence of opioid dependence and without methadone OAT
programs was conducted from June 2006 to October 2007. Three different types
of sites were categorized according to the number of veterans receiving
buprenorphine prescriptions. Five sites were categorized as “More
Buprenorphine” (i.e., with more than 40 prescriptions), three sites were
categorized into “Some Buprenorphine” (with 5-40 prescriptions), and 9 sites
were categorized as “No Buprenorphine (with 0-5 prescriptions). Sixty-two staff
members were interviewed. For all three buprenorphine sites, common provider
barriers included: (1) lack of interest, (2) stigma toward the population, (3) lack of
education, (4) resistance to change, (5) lack of provider interest, (6) abstinencebased philosophy, and (7) pain and addiction issues (19).
Thus, although a few published studies have partially examined potential
barriers to prescribing buprenorphine, these studies do not provide a
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comprehensive assessment of barriers from the viewpoint of providers. Also, a
major reason to do the present study is to determine the barriers and facilitators
reported by physicians in New Mexico.
Studies Conducted in New Mexico
Semi-structured interviews were conducted in 2011 in Albuquerque, NM
with staff from 24 substance use treatment agencies and with 8 key stakeholder
personnel (e.g. Department of Health, substance abuse advocacy groups), to
identify the gaps in opioid addition treatment availability (14). However, this
study did not specifically focus on the barriers faced by physicians in prescribing
buprenorphine in NM.
Studies Conducted Internationally
A study in Norway reported the practices, motivations and diversion of
methadone and buprenorphine in inmates enrolled in opioid maintenance
treatment (OMT) (15). Twenty-eight in-depth interviews with inmates enrolled in
12 different OMT programs were conducted. The interviewees shared that the
acquired norm of sharing drugs with others in a community was maintained even
after entering OMT in prison. Dispensing their own prescription opioids by those
who are enrolled in OMT to other individuals using illicit heroin but who are not
enrolled in OMT and having withdrawal symptoms was commonly seen as an act
of helping or was done for monetary reasons. Buprenorphine is sometimes
illegally shared by addiction patients and thus can be a drug of abuse as well as
a treatment of choice for opioid addiction.
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Since 1995, France has allowed all of the registered physicians to
prescribe buprenorphine without going through special training or acquiring any
particular license. This policy has significantly increased the number of
buprenorphine prescribers in the country and 20% of all the registered physicians
are freely treating more than 50% of the opioid use disorder patient population
with buprenorphine. The relaxed regulatory environment has made the
buprenorphine maintenance treatment feasible and safe for physicians who are
prescribing the treatment from office based settings (16).
In this study, we are trying to understand why, despite of a fact that an
efficacious drug is available to treat patients with opioid use disorder, only a
relatively few providers are licensed to prescribe buprenorphine in New Mexico.
According to New Mexico Health Care Workforce Committee Annual Report
2016, in 2015 there are total 9382 MDs and DOs licensed in New Mexico but
only 5367 (57.2%) practices in New Mexico (22). Out of these 5367 MDs and
DOs, database from SAMHSA shows that only 255 have the waiver to prescribe
buprenorphine. Per New Mexico Pharmacy Board, in last fourth quarter of 2016,
only hundred and eleven physicians have prescribed buprenorphine to minimum
of 20 patients.
In New Mexico, there are a total 9 medical specialties that may be
licensed to prescribe controlled substances:
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Table 2: Acronyms for healthcare professionals
1
2
3
4
5
6
7
8
9

MD
DO
DDS
DMD
DVM
DPM
NP
PA
OD

Doctor of Medicine
Doctor of Osteopathic Medicine
Doctor of Dental Surgery
Doctor of Medicine in Dentistry or Doctor of Dental Medicine
Doctor of Veterinary Medicine
Doctor of podiatric medicine
Nurse Practitioner
Physician Assistant
Doctor of Optometry

According to PMP there are total 5745 healthcare providers who are
actively prescribing controlled substance to minimum of one patient in last fourth
quarter of 2016 in New Mexico.
Out of which 2906 are MDS, 1015 are NPs, 580 are PAs and 227 are the DOs.
We can also conclude that in the epidemic of opioid use disorder,
healthcare providers belonging to 9 specialties have access to prescribe
controlled substances to the New Mexico population but only 2 specialties (MD
and DO) have access to treat patients with opioid use disorder.
This is a hypothesis generating study with one specific aim: To identify
the barriers and facilitators for providers in prescribing buprenorphine to treat
patients with opioid use disorder in New Mexico
The long term goal of this line of research is to decrease deaths and ED
visits related to opioid overdose in the state of New Mexico. The overall
objective of this specific initial project is to create a survey, by identifying the
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most frequent and impactful barriers faced by the buprenorphine prescribers for
treating the opioid use disorder population in NM. This study will be the first in a
series of studies designed eventually to reduce opioid mortality and morbidity by
increasing the number of providers to prescribe buprenorphine. This study is
descriptive and exploratory in nature. The rationale of the study is to better
understand the obstacles to treatment with buprenorphine as the first step in
alleviating those barriers by designing educational and informative programs;
which may facilitate and promote buprenorphine treatment, and in response,
increase the number of physician with widespread access to the medication for
opioid addicted patients. The research study has one specific aim that is
descriptive and exploratory in nature: To implement this aim we will create a new
survey that will assess the barriers associated with prescribing buprenorphine in
New Mexico for treating opioid use disorder patients.
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Chapter 2
Methodology

Initially, we reviewed 39 relevant articles to collect all the barriers and
facilitators reported by previous studies that physicians are facing for prescribing
buprenorphine nationally and internationally. We then included 28 barriers and
facilitators in our initial semi-structured interview guide created to interview New
Mexico experts on opioid abuse. Our initial interview guide also included some
questions related to buprenorphine training, motivations to become a
buprenorphine prescriber, and any obstacles or facilitators that impact providers
while becoming a buprenorphine prescriber. All 28 barriers and facilitators were
listed in the first version of our survey, and interviewees were asked to rate each
on an 11-point scale ranging from “- 5 = extreme barrier” to “+ 5 = extreme
facilitator” with “0” as midpoint of the scale labeled “neither barrier nor facilitator.
We sent all the experts and physicians a letter of recruitment prior to
interviewing each. (see appendix A). The letter explained details about the
study, assured participants that the data would be kept confidential and indicated
that the study had been approved by the University of New Mexico Human
Research Review Committee (an Institutional Review Board).
Using our interview guide, we first interviewed 5 physicians who are
experts in addiction, who already have a buprenorphine waiver, and who have
been engaged in education and training new physicians to become
buprenorphine prescribers in New Mexico. Face-to-face semi-structured
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interviews were individually conducted using an iterative approach such that
each interview informed the interviewer for subsequent interviews to enable more
informed follow-up questions. We interviewed as experts:
(1) Dr. Miriam Komaromy, Professor of Internal Medicine, University of
New Mexico
(2) Dr. Christopher Novak, Medical Director, Public Health Division, New
Mexico Department of Health
(3) Dr. Snehal Bhatt, Medical Director, Addictions and Substance Abuse
Program, Assistant Professor, University of New Mexico
(4) Dr. Leslie Hays, Family Practitioner at Espanola, addiction expert
recognized at the White House as Champion of Change in April 2016.
(5) Dr. Bruce Trigg, Former Medical Director, Public Health Division, New
Mexico Department of Health
All interviews were audiotaped and saved on encrypted UNM computers.
All 5 experts appeared highly motivated and gave us excellent feedback about
barriers and facilitators for prescribing buprenorphine in New Mexico. We
modified the interview guide slightly after each interview before conducting the
next interview. The 5 expert interviews resulted in several new barriers being
added to our interview guide list of barriers. Expert interviews also resulted in
some minor wording changes to the extant listed barriers.
We then recruited 10 physicians with buprenorphine waivers who are
prescribing buprenorphine from office based settings (OBS) and 10 physicians
prescribing buprenorphine from Opioid Treatments Programs (OTPs).
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Recruitment was by word-of-mouth and by using the online publicly available
directory for buprenorphine prescribers and from the National Directory of Drug
and Alcohol Abuse Treatment facilities for 2015. To collect perceived barriers
and facilitators throughout New Mexico, in each of the two groups we recruited 5
physicians from urban and 5 physicians from the rural area. It was presumed
that barriers may vary between urban locations (Albuquerque metropolitan area,
Santa Fe, and Las Cruces practice areas) and rural practice areas (all other
areas in NM). Individual telephone and face-to-face semi-structured interviews
were conducted. All the interviews were digitally audiotaped with de-identified
recordings stored on an encrypted UNM computer. No one had the access to
recordings except myself and Dr. Teddy Warner, my thesis director.
Qualitative interviews typically proceed iteratively with subsequent
interviews building upon what is learned in earlier interviews. Qualitative
approaches tend to be superior to quantitative methods for uncovering novel
information because they allow for more diversity in responses as well as for the
ability for researchers to adapt to new problems and issues during the research
process (21). Provider interview questions were informed and modified based on
what we learned from interviewing our expert consultants. As each provider
interview proceeded, we asked additional questions suggested by interviewee’s
responses to the listed questions. As different interviews proceeded, we added
additional questions to the list of basic questions to be asked of all interviewees,
including sometimes adding new barriers to our list of barriers.
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Various specific questions were linked with each source of barriers. After
completing each barrier question, we asked a rating-scaled question designed to
assess the strength or importance of the various barriers. In qualitative
interviewing, emergent questions often occurred that derived from interviewee
responses that we were not be able to anticipate, and thus we did not restrict
ourselves to particular questions for any given interview. Our approach was to
emphasize the need to understand barriers and facilitators to prescribing
buprenorphine for opioid disorder patients, that is, to learn about behaviors and
patterns that may affected the accessibility of buprenorphine to the opioid use
disorder population in New Mexico from the viewpoints of the providers. We
analyzed the interview data soon after finishing each interview so that what we
learned in each interview informed each subsequent interview in an iterative
fashion that is standard in qualitative interviews and focus group approaches
(21). Analysis of interview data focused primarily on identifying new barriers or
facilitators to add to our list of such, as well as to consider whether new openended questions about barriers and facilitators should be asked in subsequent
interviews of providers.
All the barriers and facilitators expressed by providers that are interviewed
were extracted, and a new survey was constructed with rating scaled questions
that ask survey respondents to rate the importance of each listed potential barrier
or facilitator in influencing their decision to become buprenorphine prescriber.
We expect that the collected information from the 20 interviews have identified
the relevant barriers and to understand physician opinions, motives and beliefs
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about treating opioid addicted patients in NM. The later interviews did not
generate new barriers or facilitators, suggesting strongly that our list had reached
saturation. However, we also included the barriers from the previous published
literature even if our interviewees do not identify them. After a final survey draft
was produced in collaboration with my thesis committee and myself, Dr. Warner
and I then cognitively tested the survey draft with 3 volunteer addiction medicine
physicians from the UNM Alcohol and Substance Abuse Treatment Program
(ASAP). My thesis director, Dr. Warner, is an expert and instructor in survey
methods and cognitive interviewing taught me those approaches in this project.
Information related to these barriers gained from the interviews were then
used in creating a survey. This survey will be used in NM for a future follow up
study to assess barrier frequency and importance in inhibiting prescribing
buprenorphine. Based on interviews with 10 urban and 10 New Mexico providers,
we now have preliminary survey data (N=20) that can be used to support a future
grant proposal to fund a study to assess the prevalence of barriers and
facilitators in New Mexico and potentially in other states as well.
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Figure 1: Methods Used to Construct a New Survey of Barriers and Facilitators
for Physicians in Prescribing Buprenorphine in Treating Opioid Disorder Patients
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Chapter 3
Results
We interviewed 12 family practitioners, 1 internist, 2 preventive medicine
physicians, 1 psychiatrist, 1 addiction psychiatrist, 1 pediatrician, 1 interventional
cardiologist and 1 emergency medicine specialist. Two were also addiction
medicine specialists. Ten were strictly prescribing buprenorphine from office
based settings, 9 are prescribing mostly methadone and often buprenorphine
from a Medication Assisted treatment program (MAT), and 1 physician
prescribed just methadone from MAT. Initially, seven general open-ended
questions were asked of these physicians to get them to explain their motivation
for getting buprenorphine training and for treating opioid use disorder patients.
Responses from our first 7 open ended questions asked from 20 physicians in
NM are summarized below:
1. Why did you decide (or decide not) to become a buprenorphine prescriber
yourself?
Out of 20 physicians interviewed, 35% said that they decided to do the
buprenorphine training due to a need in the society; 25% said that they did
the training as a part of their job and hence are prescribing buprenorphine
now; 15% did the training while working as resident; 10% were motivated and
encouraged by other physicians. Only 1 did the training after retirement from
his specialty to establish another career pathway. One already has the DEAX license, and one was not a buprenorphine prescriber.
2. Were there any factors that acted as barriers to you doing so?
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Seventy-five percent physicians said that there were no barriers in doing the
training; 1 said training itself is a barrier in becoming a buprenorphine
prescriber; 1 found difficulty finding a training in NM; 1 drove to Washington
DC from NM in 2002 when training was not available easily in all states; 1
said the online course should be used instead of onsite; and, 1 has never
done the training but is interested in doing it in near future.
3. Where there any factors that facilitated you becoming a prescriber?
Thirty percent of physicians said that UNM Project ECHO training facilitated
them to do a training; 10% said that they had strong support from work; 25 %
said nothing facilitated them to do the training; 10% said that they were
already working in a methadone and detox clinic which facilitated them to do
the training; 1 took the first offered training in San Francisco, CA and all the
expenses were covered by the FDA; 1 said working in a rural area where
there were no addiction specialist physicians inspired him to do the training; 1
said he already had a DEA-X license; 1 said his clinical practice has
established patients so training helped him to take care of these patients and
1 has never done the training.
4. Did you feel more confident in prescribing buprenorphine after doing half and
half training?
Seventy percent physicians feel confident that they are able to prescribe
buprenorphine after the training; 1 said training is not sufficient or effective
and it is just a basic course; 1 did not feel comfortable after doing the training;
1 said the course needs to be more comprehensive and advance; 1 said
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training was helpful but it was unnecessary to have it to get a license for
prescribing buprenorphine; and one was not a prescriber.
5. What are the things that you like (or might like) or things that inspire you to
continue working as a buprenorphine prescriber?
Fifty percent physicians said it is very rewarding to treat these patients and
observing a great change in their lives; 10% said that its been recognizing as
a disease model now; 10% said its cost effective to treat these patients; 10%
said buprenorphine is a very effective drug; another 10% said that they will
continue to work as there is a strong need in the society; 1 said establishing
care for patients and transferable prescriptions are very helpful; 1 said its
pretty flexible and easy to treat opioid use disorder (OUD) patients with a
prescribed drug also its highly divertible so OUD patients can get it easily on
streets and use it; 1 said there is a significant need of physicians in our
society; and 1 was not the prescriber.
6. What are the things that you do not like or things that inhibit you from working
as a buprenorphine prescriber?
Twenty five percent said nothing could stop them from prescribing
buprenorphine; 15% said patients behavior as being dishonest, nasty attitude
or their friends circle; 15% physicians said prior authorization is a hassle;
10% said insurance restriction like partial refill or refill for only 30 days is a
problem; 10% said patients have very sad stories which make them
emotional; 1 said 30 cap rule is ridiculous; 1 said not a great success in
treating these patients; 1 said isolation from medical community and

24

restriction from other clinicians to take these new patients; 1 said already
engaged in other responsibilities so hard to find time to treat these patients;
and 1 was not the prescriber.
7. Do you have any comments or explanations about the process of providers
getting trained and licensed to prescribe buprenorphine in treating their opioid
addicted patients?
Forty percent of physicians mentioned nothing; 10% said training was worth it
and a network should be available to support and answer questions; 1 said
there is a need to train non-physician staff too and educate patients for both
methadone and buprenorphine; 1 said there is a need for more marketing to
promote the drug; 1 said the 275 cap rule is a good step; 1 said training
needs to be more comprehensive; 1 said training needs to be shortened; 1
said that it should be an online training; 1 said it is easy to do a training; 1
said NPs and PAs should become prescribers; and 1 was not a prescriber.
Responses of each of the 20 physicians interviewed for this study are shown
in Table 3 below.
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Table 3: Responses of 20 Physicians to 7 Open-ended Questions about
Prescribing Buprenorphine for Opioid Disorder Patients.
Question
Physician
Interviewee

1. Why did
you decide (or
decide not) to
become a
buprenorphine
prescriber
yourself?

2. Were
there any
factors
that
acted as
barriers
to you
doing
so?

3. Where
there any
factors that
facilitated your
becoming a
prescriber?

4. Did you
feel more
confident in
prescribing
buprenorphine
after doing
half and half
training?

5. What are
the things that
you like (or
might like) or
things that
inspire you to
continue
working
as a
buprenorphine
prescriber?

6. What are
the things that
you do not like
or things that
inhibit you
from working
as a
buprenorphine
prescriber?

7. Any
comments or
explanations
about
the process of
providers
getting
trained and
licensed
to prescribe
buprenorphine

Encouraged
by other
physician.
Due to need in
the community

No

UNM Echo
training, Free
class

Yes

Rewarding

People are
dishonest

Nope

Job
requirement

No

Travelled to
SFO as it was
the first
training. All
expenses
were covered
by FDA

Yes

2

Establishing
care for
patients.
Transferable
prescriptions

Prior
authorization
Partial refill

Need to
trained
non-physician
staff, educate
physician
for both
buprenorphine
And methadone

Job
requirement

No

Support from
work

Yes

Rewarding

Sad stories of
patients

No

3

Motivated
after seeing
colleague in
same practice

No

No

Yes

Rewarding

Prior
authorization

No

Job
Requirement

No

UNM Echo
training,

Yes

Rewarding

No

5

Need in the
community

No

UNM Echo
training,

Yes

6

OUD
recognized as
a disease now

Getting
emotional

Need more
marketing and
recruitment.
Changing the
cap to 275 is a
good step.

Need in the
community

No

No

Yes

Rewarding

7

Prior
authorization
Not having
access to
speak for
more
complicated
addiction
population

Training worth
it

Support from
work

Not sufficient
or effective, it
is just basic

Rewarding

None

No

No

1

4

8

Need in the
community
Job
requirement
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9

10

11
12

13

14

15

16

17

18

Need in the
community as
mostly Hep c
patients with
OUD

Training
itself as a
barrier as
you
cannot
prescribe
without it

Working in a
rural area
where no
Addiction
providers are
present

Yes

buprenorphine
is an effective
drug

None

Training is
good.
network is
available to
ask question

Job
requirement
as trained as a
resident

No

DEA-X license

Yes

Significant
need of taking
care of these
patients
Low supplyhigh demand

Insurance did
not allow to
prescribe for
more than 30
days

No

Need in the
community

No

Easy access
to training

Yes

Need in the
society

Nastiness of
patient

Training worth
it

Already have
a DEA-X
license

No

Clinical
practice has
already some
established
patients

Did not feel
comfortable
after doing
that training

Need in the
society

Too busy in
other things

Need more
comprehensive
training

Need in the
community
Shortage of
specialist in
community

Looking
for a
class in
NM

No

Training was
helpful,
Unnecessary
to have
license
Requirement
to prescribe
buprenorphine

Rewarding,
Cost effective
to treat these
patients

Isolation from
medical
community,
Restriction
from other
clinician to
take these
patients

Should be an
online class
instead
of long 8 hour
class.

Retired from
other
profession so
decided to
treat OUD
patients

NO

No

Yes

Rewarding

Company of
patients

No

Due to opioid
epidemic in
our society

Online
course is
easy to
do

Working in a
methadone
clinic
promotes to
become a
buprenorphine
prescriber

Yes

Rewarding

30 cap rule is
ridiculous

No

While working
as a resident,
job
requirement

Drove to
DC for
training
in 2002

Working in a
detox clinic

Yes

Not see a good
result with
methadone,
few patients do
very well on
buprenorphine.

Not seeing
much success

No

During
residency see
many patients
with opioid so
decide to treat
and get
licensed for
buprenorphine

No

No , very easy

Course is very
basic, need to
be more
advance

Flexibility
Ability to treat
OUD patients
with prescribe
drug,
Highly
divertible

No

PA, NP
become
prescriber

Course
offered by
FDA

No

UNM paid for
the training

Yes

Consider as a
disease now

No

Need to
shortened the
training
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Job
requirement
Need to
provide
buprenorphine
to pregnant
patients in
MDC

NO

Availability of
training
through UNM

yes

Rewarding,
Bring change
in people life

Patient
behavior

Easy to do

Not a
prescriber

Don’t
know
how to
take the
training
and
where
the
training
take
place
Do not
use
computer

Not a licensed
buprenorphine
prescriber

Not a licensed
buprenorphine
prescriber

Not a licensed
buprenorphine
prescriber

Not a licensed
buprenorphine
prescriber

Not a licensed
buprenorphine
prescriber

After asking our 20 physicians the 7 open-ended questions for which we
summarize responses above, interviewees rated each of our initial list of 32
potential barriers and facilitators using an 11-point rating scale:
- 5 = strong barrier to 0 = no barrier or facilitator to + 5 = strong facilitator
We asked each physician to indicate the degree which they believe, based on
their overall experience in the addiction field, to what degree each listed factor is
a barrier or a facilitator or neither for providers in general for getting licensed to
prescribe buprenorphine. Mean responses and standard deviations are shown in
Table 4 below. Means above 0 are on average rated as a facilitator, and means
below 0 are on average rated as a barrier, given the scale shown above.
Twenty-one of our 32 listed factors were rated with mean values that are
negative, that is, on the barrier end of the scale, and only 10 factors are rated
with values above 0 on the facilitator end of the scale. One item had a mean
rating of 0.0, indicating on average it was seen as neither a barrier nor a

28

facilitator. It should be noted that the means are rather moderate in magnitude
given the barrier and facilitator labels. For example, the lowest rated barrier had
a mean of only - 2.48 on a 0 to – 5 scale, suggesting that on average it is only
seen as a moderate degree barrier. Similarly, the highest rated facilitator only
had a mean of + 2.64, indicating on average that it was seen as a moderate level
facilitator.
Also, it should be noted that both barrier and facilitator factors had
variability in their standard deviations. A standard deviation on a rating scaled
item can be interpreted as an indicator of the degree of agreement or
disagreement, with higher SDs indicating greater variability and disagreement
among respondents. On rating scales of 11 points, a standard deviation of about
2.00 would be common, and thus standard deviations above that value should be
interpreted as indicating notable disagreement among our 20 respondents. It
should be noted from Table 4 below that the majority of negatively rated items
(i.e., barriers), as well as the majority of positively rated items (i.e., facilitators)
had standard deviations > 2.00, indicating considerable variation in opinion
among interviewees. In addition, one should recognize that it may be logically
possible for an issue to be a barrier for some providers but a facilitator (or at least
neutral) for other providers, and vice versa.
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Table 4: Factors Rated by Physicians (N=20) as Barriers (mean ratings < 0.00)
to Becoming a Buprenorphine Prescriber

Barriers (items rated < 0)

Mean

SD

1

Previous restriction for NPs and Pas

-2.48

2.66

2

Limitation by third party payer

- 2.30

1.67

3

DEA oversight

- 2.10

2.33

4

100/30 cap rule

- 1.99

2.00

5

Diversion

-1.83

1.84

6

Refer to other consultant or specialist

- 1.57

2.44

7

Medical records for DEA auditing

- 1.57

2.31

8

Insufficient inventory at pharmacies

- 1.49

2.14

9

Extra vigilant in clinic

- 1.43

1.38

10

Pharmacies do not carry B\buprenorphine

- 1.29

2.31

11

Insurance company’s reimbursement

- 0.97

2.49

12

Stigma to my clinic

- 0.79

2.05

13

Buprenorphine prescriber training

- 0.73

1.63

14

Security threat to my clinic

- 0.73

1.08

15

Dispensing buprenorphine daily

- 0.62

2.28

16

Comorbidities of patients

-0.44

2.48

17

Clinical staff are not sufficiently trained

- 0.33

2.74

18

Medicare reimbursement

- 0.24

2.04

19

Frequent visits of patients

- 0.14

2.60

20

Send prescriptions directly to pharmacies via e-prescription

- 0.11

1.17
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or fax
21

Medicaid reimbursement

- 0.11

2.52

Table 5: Factors Rated by Physicians (N=20) as Facilitators (mean ratings >
0.00) to Becoming a Buprenorphine Prescriber
Facilitators (items rated > 0)

Mean

SD

1

Treating addicted patients in my practice

+ 2.64

3.32

2

Realizing the high need for addiction providers

+ 2.22

2.53

3

Telemedicine clinic to treat patients

+ 1.47

2.32

4

Treating patients with opioid use disorder is profitable

+ 1.09

2.58

5

Any agency helps in cost

+ 0.98

1.67

6

Patients might experience serious buprenorphine side effects

+ 0.89

1.73

7

Checking Prescription Drug Monitoring Program

+ 0.88

2.26

8

Support from administration

+0.57

3.00

9

DEA-X license renewed every 3 years

+ 0.21

0.83

10

New 275 cap rule

+ 0.02

2.88

11

Effort in applying for an initial DEA-X license

0.00

1.84

Initially, after reviewing all the relevant published literature, our interview
guideline started with 28 factors as potential barriers and facilitators. Through our
iterative approach we kept adding the factors and after interviewing 5 experts, 20
physicians and checking cognitively with 3 addiction medicine specialists,
ultimately our final survey showed 37 factors to be rated on a rating scale which
could indicate an issue as being either a barrier or facilitator.
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From Table 5 above, it can be seen that only 11 items were on average
rated to be very strong barriers (i.e., means near or > - 1.00): (1) Previous
restriction for NPs and Providers; (2) Limitation by third party payer; (3) DEA
oversight; (4) 100/30 cap rule; (5) Diversion; (6) Refer to other consultant or
specialist; (7) Medical records for DEA auditing; (8) Insufficient inventory at
pharmacies; (9) Extra vigilant in clinic; (10) Pharmacies do not carry
buprenorphine; and (11) Insurances company reimbursement. In contrast from
Table 4, only 6 factors show mean ratings of near or above + 1.00, indicating
they are seen as meaningful level facilitators: (1) Treating addicted patients in my
practice; (2) Realizing the high need for addition providers; (3) Telemedicine
clinic to treat patients; (4) Treating patients with opioid use disorder is profitable;
(5) Any agency helps in cost; and (6) Patients might experience serious
buprenorphine side effects.
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Chapter 4
Discussion
The current research is innovative because it represents a substantive
departure from the status quo by identifying the barriers faced by the physicians,
which limit opioid dependent patients from seeking buprenorphine treatment.
The current research is significant because it helped us to create a survey which
can be used to identify the extent and importance of the barriers that restrict
physicians from prescribing buprenorphine. This contribution is also important
because our new survey can potentially be used in any state of the United States
to identify these barriers. The survey of providers will be conducted in a followup study, and results from the survey will help to design educational and
informative programs, which will facilitate and promote buprenorphine
prescription.
In New Mexico, the opioid overdose death and ED visits are rising at an
alarming rate, which is seriously affecting the residents and the state. Data
collected from the current study conducted in New Mexico shows that providers
certain barriers exist for physicians in either prescribing buprenorphine or
becoming a licensed to be a prescriber.
We were able to identify 21 barriers from the study: (1) previous
restriction for nurse practitioners and physician assistants,(2) limitation by third
party payer,(3) DEA oversight, (4) 100/30 cap rule (5) diversion, (6) refer to other
consultant or specialist, (7) keeping a separate medical records for DEA auditing,
(8) insufficient inventory at pharmacies, (9) being extra vigilant in clinic, (10)
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pharmacies do not carry buprenorphine, (11) insurance companies (12) Medicaid
and (13) Medicare reimbursement issues, (14) stigma to the clinic, (15)
buprenorphine prescriber training, (16)security threat to the clinic, (17)
dispensing buprenorphine daily to OUD patients, (18) comorbidities of patients,
(19) clinical staff are not sufficiently trained, (20) frequent visits of patients and
(21) sending prescriptions directly to pharmacies via e- prescription or fax.
Our study also identified 10 facilitators for providers who may desire to
prescribe buprenorphine in treating opioid use disorder patients in New Mexico:
(1) treating and taking care of opioid use disorder patients in clinical practice, (2)
realizing the high need for addiction providers, (3) telemedicine clinic to treat
OUD patients, (4) treating patients with opioid use disorder is profitable, (5)
funding from any agency, (6) patients do not experience serious buprenorphine
side effects, (7) Prescription Drug Monitoring Program, (8) support from
administration, (9) DEA-X license renewed every 3 years; and (10) new 275 cap
rule.
Also in comparing the results from both our provider groups (physician
prescribing buprenorphine from office based settings vs. physicians prescribing
buprenorphine from Opioid treatment facilities), we did not find major differences
in the answers provided by the physicians except that physicians working in OBS
have problems in sending referral to psychologist, social worker, psychiatrist etc.
This is not an issue in OTP as all the related specialties work (psychologist,
social worker, psychiatrist) together under same roof. However, differences of
opinion from those who practice in urban areas compared to those who practice
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in rural areas on the DATA 2000 100/ 30 CAP rule were detected. Rural
providers are more willing to treat more patients but due to 100/30 cap rule and
limited number of appointment slots, they cannot actually see more patients.
Some patients died due to long waiting (estimate 18 months long). In contrast,
physicians working in urban areas have open slots for appointments and they
rarely reach the 100 cap rule limit.
In addition to identifying provider perceptions of the barriers and
facilitators in New Mexico during this pilot study, interviews with the providers
also gave us some important information and support for recommendations
which may help in improving the infrastructure for the NM opioid maintenance
treatment program.
Some common thoughts and recommendation given by the 20 providers
on the following important topics are as follows:
Buprenorphine Half and Half Training
Many physicians stated that it is much easier to do buprenorphine half and
half training at University of New Mexico in Albuquerque, NM compared to the
past when physicians had to travel to other states for the training. After
completion of the training, UNM Project ECHO helped the physicians to apply for
DEA-X license. Few mentioned that training is effective, easy-going but some
consider it is not sufficient and needs to be more elaborated.
Also, physician recommend that it is easier to become buprenorphine prescriber
if the resident physicians complete the buprenorphine training during their
residency.
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Recommendations to facilitate prescribing buprenorphine in NM
Physicians who recently started prescribing buprenorphine are hesitant of
taking care of complicated patients due to co morbidities. A network should be
establishing which direct the complicated patients with co morbidities to
experiences physicians and stabilized patient to those physicians who just
started prescribing buprenorphine. Another network/ help hot line should be
established which can help and answer physician’s questions related to
buprenorphine treatment 24/7. Hundreds of people die in New Mexico due to
overdose deaths while waiting for their appointment. A generalized system
should be developed in NM which help opioid use disorder patients to find
physicians who have open slots for appointments and are accepting new
patients. Similarly, some physicians become buprenorphine prescribers as a
requirement from their job, especially if they are working in Metropolitan
Detention Center, Federally Health Qualified Clinics or New Mexico Department
of Health. Some federally health qualified clinics receives an HRSA grant to treat
OUD patients. Non-physicians staff including nurses, physician assistants
should be trained too to help in treating and answering physician’s questions.
Physicians, nurses and physician assistants should educate patients for both
buprenorphine and methadone and give them an option to choose any of the
medication by themselves. Majority of the physicians mentioned that prior
authorization and partial refill is a hassle for physician. Like France,
buprenorphine X waiver licenses should not be needed to become prescriber and
any physicians should prescribe it from OBS in US. Also, physicians are
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hesitant to become buprenorphine prescriber due to DEA auditing. Amendments
should be made to make the system friendlier and flexible. Exposure and
awareness should be created among physicians to consider addiction as a
disease model and not a taboo. In addition, we need a better marketing
techniques for buprenorphine promotion in NM. All opioid use disorder (OUD)
patients should be treated with respect and dignity. Physicians who are working
in Behavioral Health clinics or well-established clinics like University hospital or
FHQC have additional support in becoming a prescriber. Working in rural areas
where no treatment facilities available for opioid use disorder patients also
motivated the physicians to become buprenorphine prescriber. Some physicians
get inspired by their colleagues prescribing buprenorphine and become the
prescriber. ICD-10 has established codes for OUD which is helpful for the
medical record keeping. Physicians treating patients for Hepatitis get motivated
to becomes buprenorphine prescribers as many of the Hepatitis B and C patients
are also IV drug abusers. Project Echo at UNM is excelling for helping
physicians to treat both Hepatitis C and OUD patients. After retirement, some
physicians work as a buprenorphine prescriber and generate a sound income.
The ability to treat patients with buprenorphine is flexible and easy to follow
compared to methadone. Also, buprenorphine is cost effective compared to
expenses accounts for complications and manifestations of opioid use disorder.
Being highly divertible is a positive aspect for buprenorphine as its motivated the
patients to seek help and get legal buprenorphine prescription from physicians.
One physician mentioned that buprenorphine is more effective for higher
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socioeconomic patients who have OUD due to prescription painkillers and is
more beneficial for smokers than non-smokers.
Major and Minor barriers identified during Interviews
There are multiple objectionable restrictions from the government like 100/30
cap rule, DEA –X license or auditing. Patients social circle and past experience
are major barrier for their recovery. Narcotic anonymous groups are not as
beneficial and It is also hard to titrate buprenorphine in patients who are already
taking benzodiazepine, sleep pills, alcohol or other antipsychotics drugs. Some
physicians believe that treating opioid used disorder patients is not profitable due
to inflation and reimbursement. In fetal-maternal clinics, security threats to the
staff are mostly from partners and not from opioid use disorder pregnant patients.
In jail buprenorphine are only provided to female inmate pregnant patients. After
delivering babies, no further buprenorphine treatment is given. Some physician
mentioned that the level of support is adequate to become a buprenorphine
prescriber. However, due to work load many physicians are unable to take care
of opioid use disorder patients from office based settings. In New Mexico, there
are some OUD patients who have no medical insurance and either did not qualify
or have never applied for Medicare or Medicaid. Such patients have never
received any kind of maintenance treatment. Physicians treating substance
abuse patients become isolated from rest of the medical community and some
clinicians are hesitant to take OUD patients as a referral. Some insurance
companies restricted the treatment for 15 days or a month supply creating a
huge barrier for both physician and patient for continuity of care. Incompliant
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patients who are missing follow-ups is also a barrier for a continuity clinic. The
30 cap rule is the major barrier in both urban and rural settings. The 100 cap rule
is a barrier in the rural area due to insufficient number of physicians in remote
areas. The 275 cap rule is effective but it has its own limitations. Probation, pay
role and incarceration are the common barriers in treating already established
patients on buprenorphine. Referring to other specialties like psychologist,
counselor, social worker or any physician specialist is not easy and convenient
from office based settings. The DEA approach is not useful and diversion is
another barrier for lower socioeconomic status.
Study Limitations
Our study has some limitations. Initially we decided to interview two
groups, one who prescribed methadone and one who were buprenorphine
prescribers. In the beginning, we interviewed one methadone prescriber and
found that the physician had a very limited or zero knowledge on buprenorphine.
While recruiting more methadone prescribers, we found out that 90% of
methadone prescribers had already a DEA-X waiver to prescribe buprenorphine.
We then changed our selection strategy and recruit two buprenorphine prescriber
group, one working in office based setting and one working in MAT program.
Because, New Mexico has very few MAT’s (less than 20) recruiting
buprenorphine prescribers from these facilities was very difficult. We sought help
from our experts and also contacted physician with the help of National Directory
of Drug and Alcohol Abuse Treatment facilities 2015. Also as there are only
hundred and eleven active buprenorphine prescribers in the state, it was also
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challenging to recruit them in the study. We only recruited 20 physicians
throughout the state, and so generalizability is another issue. For the qualitative
study, it was sometimes difficult to filter the interviewee thoughts clearly. On
some occasions, the conversation went off the tangent and it was difficult to
judge whether it was a personal experience, a true barrier or a difference of
opinion. Finally, data was extensive, which made it difficult to analyze.
Conclusion
Because this is a pilot study our results are not conclusive. Our team is
committed long term to minimize the barriers that are now making buprenorphine
treatment inaccessible to large numbers of opioid use disorder patients in New
Mexico and other states. Identification of such barriers in this study has allowed
us to design a survey which can potentially be used anywhere nationally to
identify the barriers that may vary from state to state. A statewide survey of
providers is now called for to get better estimates of provider ratings of barriers
and facilitators in trying to become licensed to prescribe buprenorphine in
treating their opioid use disorder patients. This statewide survey must include
both Buprenorphine providers and providers who do not prescribe Buprenorphine
to enable understanding of barriers. A follow-up grant funded study should be
then conducted by designing educational and informative programs that will help
to reduce barriers and will encourage physicians to become licensed
buprenorphine prescribers. Finally, if the number of physicians who are licensed
to prescribe buprenorphine is meaningfully increased, then investigators will
follow trends in opioid deaths and ED visits to determine if the overall objective of
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reducing these barriers and thus reducing opioid related death rates is achieved
in the years ahead. In addition, the data acquired for this study could also
support a separate follow-up study to assess barriers to buprenorphine
prescribing across multiple states.
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Appendix A: Recruitment letter for Physicians

The University of New Mexico

Health Sciences Center
School of Medicine
Department of Family & Community Medicine
MSC 09 5040
1 University of New Mexico
Albuquerque, NM 87131-0001
505-453-8710; FAX 272-8045

Name
Address
Address
Address
Dear Dr:
We need your help, please! We would greatly appreciate 30 minutes of your time to interview you about your
experiences related to treatment of patients with opioid substance abuse disorder. Physicians identified from
the New Mexico list of licensed physicians are being solicited for these interviews, including physicians who
have been licensed by the DEA and are actively prescribing Buprenorphine. However, we also need to
interview physicians who treat opioid addicted patients without using Buprenorphine.
If you are willing to consider being interviewed, please call Dr. Kanwal Qidwai (cell: 713-449-3536) or email
her (kqidwai@salud.unm.edu ) to schedule an interview time and place convenient to you, or she can
interview you on the phone if that works better for you. As my co-investigator, Dr. Qidwai is a 3rd year resident
physician in the Preventive Medicine Program of the Dept. of Internal Medicine at UNM School of Medicine,
and next year she will commence a Fellowship in Addiction Medicine.
This is an unfunded preliminary study which will help us to understand the barriers faced by physicians for
prescribing Buprenorphine in New Mexico. The data will be used to design follow-up studies to improve
treatment of people with opioid use disorder for which we will later seek funding from the National Institutes on
Drug Abuse.
Because this study is unfunded, we have no money to offer you as compensation. Immediately after the
interview, your name and other identifiers will be separated from our interview notes, and from digital
recordings of the interviews. Interview tapes will be destroyed by June 30, 2017.
Of course, you may choose not to be interviewed without any adverse consequences. No one except me and
Dr. Qidwai will have access to the identities of physicians whom she interviews, nor of course, to any
individual level data obtained from interviews. Aggregate results of this interview study will be used as
preliminary data in future grant proposals, presented to various professional audiences, and submitted for
publication consideration.
This study has been deemed “exempt” from further IRB oversight, and this letter serves as the approved
Informed Consent Form. Completion of the interview will constitute your provision of informed consent for our
interview study. If you have questions about this study, please contact me (cell: 505-453-8710; email:
twarner@salud.unm.edu ). If you want to speak to someone about this study other than someone on the
research team, call the Human Research Review Committee at 505-272-1129.
Thanks very much,

Teddy Warner, Ph.D.
Research Professor
Department of Family & Community Medicine
School of Medicine
University of New Mexico

Kanwal Qidwai, M.D.
Resident Physician PGY-3
Preventive Medicine Program
Department of Internal Medicine
School of Medicine, Univ. of New Mexico

(cell: 505-453-8710; email: twarner@salud.unm.edu )

(cell: 713-449-3556; email: kqidwai@salud.unm.edu )
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Appendix B: Survey of Providers of People Who are Addicted to Opioids

Survey Objectives. Our survey is trying to identify barriers and facilitators for
prescribing buprenorphine for providers who treat patients with opioid use
disorder.
By barrier, we mean events, actions, rules, processes and regulations
that make
the process of prescribing Buprenorphine for patients with opioid use
disorder more difficult.
By facilitator, we mean events, actions, rules and regulations that make
the process of prescribing Buprenorphine for patients with opioid use
disorder easier.
We need to assess providers who prescribe Buprenorphine and providers who
do not.
Identifying such barriers and facilitators may help in the design of programs in the
future
that may help recruit and support providers to use Buprenorphine in
treating their patients.
This survey takes most providers about 10 minutes to complete.
Thanks very much for taking your time to complete our survey!
Survey Instructions. On the next 2 pages is a list of factors that may or may
not be barriers or facilitators for providers who have already become licensed to
prescribe Buprenorphine or providers who are trying or considering becoming
licensed to treat the patients with opioid use disorder
with Buprenorphine.
For each item listed, please use the rating scale provided at the top of each
page:
- 5 = strong barrier
facilitator,

to

0 = no barrier or facilitator

to

+ 5 = strong

to indicate the degree to which you believe, based on your overall experience in
the addiction field,
that each listed factor is a barrier or a facilitator or neither for providers in
general
for getting licensed to prescribe Buprenorphine.
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Strong barrier
-5
-4
-3

Factor
1. Providers not realizing that our society has a high need for
addiction providers
2. Providers having to treat patients with opioid use disorder in their
practice
3. The effort in applying for initial DEA-X license
4. DEA oversight is too burdensome or
not acceptable to providers
5. Treating patients with opioid use disorder would be stigmatizing to
a provider’s clinic
6. Time and effort needed to do Buprenorphine prescriber training is
too great
7. Initial 30 cap rule limiting the number
of patients that providers can treat during
st
their 1 year of licensure
8. 100 cap rule limiting number of patients that providers can treat
after initial year of licensure
9. New 275 cap rule limiting number of patients that providers can
treat after getting a waiver
10. Having to maintain a separate medical record of Buprenorphine
prescriptions for DEA auditing
11. Treating patients with opioid use disorder being a security threat
to a provider’s clinic
12. Patients possibly giving or selling their Buprenorphine to people
in the community
13. Patients may experience serious side effects from taking
Buprenorphine
14. Clinical staff being not sufficiently trained or experienced to
support prescribing Buprenorphine
15. Having to treat other comorbidities of patient with opioid use
disorder
16. Insurance companies possibly not reimbursing for treating
patients with opioid use disorder
17. Insurance companies possibly limiting how to treat patients with
opioid use disorder
(e.g., prior authorization, refills for Buprenorphine films or tablets)
18. Medicare possibly not reimbursing for treating patients with
opioid use disorder
19. Medicare possibly limiting how to treat patients with opioid use
disorder
(e.g., prior authorization, refills for Buprenorphine films or tablets)
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-2

Neither
-1
0

+1

Strong facilitator
+2
+3
+4

+5

Factor

Strong barrier
-5
-4
-3

20. Medicaid possibly not reimbursing for treating patients with
opioid use disorder
21. Medicare possibly limiting how to treat patients with opioid use
disorder
(e.g., prior authorization, refills for Buprenorphine
22. Any agency other than Federal or State helps with cost for
treatment
23. Clinic administration may not support providers treating patients
with opioid use disorder
24. Having to send Buprenorphine prescriptions directly to
pharmacies via e-prescription or fax
25. Treating patients with opioid use disorder is profitable

26. Having to dispense Buprenorphine tablets or films daily in the
clinic to patients with opioid use disorder
27. Patients with opioid use disorder needing more frequent visits
with providers
28. Needing to be extra vigilant in the clinic with patients with opioid
use disorder patients due to forging behaviors
29. Having to check the Prescription Drug Monitoring Program
30. Needing the ability to use telemedicine clinic to treat patients
with opioid use disorder
31. Local pharmacies not carrying Buprenorphine
32. Pharmacies that do carry Buprenorphine not having sufficient
inventory of Buprenorphine
33. Needing to refer patients with opioid use disorder to consultants
or specialists for higher level of care
34. On site access to counselling & case management
35. Having to treat patients with widely different socioeconomic
status
36. Having to do urine drug testing
37. Some other barrier or facilitator (please state):

Please continue to the last page of this survey.
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-2

Neither
-1
0

+1

Strong facilitator
+2
+3
+4

+5

We need you now to answer just a few questions so that we understand the
backgrounds
of providers answering this survey.
1. What is your gender:

____ Male

2. What is your age:

____ years

____ Female

3. What is your medical specialty?

4. In what city or town do you practice?
________________________________________
5. How many years have you practiced medicine after completing training?
____ Years
6. How many years have you treated patients with opioid use disorder?
____ Years
7. How many years have you prescribed Buprenorphine?
____ Years
8. Please estimate how many total patients for whom you have prescribed
Buprenorphine:
____ Patients
Thanks again very much for completing our survey!
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